JP5261374B2 - 抗ウイルス性ピリミジンヌクレオシド誘導体 - Google Patents

抗ウイルス性ピリミジンヌクレオシド誘導体 Download PDF

Info

Publication number
JP5261374B2
JP5261374B2 JP2009508479A JP2009508479A JP5261374B2 JP 5261374 B2 JP5261374 B2 JP 5261374B2 JP 2009508479 A JP2009508479 A JP 2009508479A JP 2009508479 A JP2009508479 A JP 2009508479A JP 5261374 B2 JP5261374 B2 JP 5261374B2
Authority
JP
Japan
Prior art keywords
compound
valine
formula
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009508479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536188A (ja
JP2009536188A5 (enExample
Inventor
クリストファー・マクギガン
ヤン・バルザリーニ
マルコ・ミリオーレ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
University College Cardiff Consultants Ltd
Original Assignee
Katholieke Universiteit Leuven
University College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven, University College Cardiff Consultants Ltd filed Critical Katholieke Universiteit Leuven
Publication of JP2009536188A publication Critical patent/JP2009536188A/ja
Publication of JP2009536188A5 publication Critical patent/JP2009536188A5/ja
Application granted granted Critical
Publication of JP5261374B2 publication Critical patent/JP5261374B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2009508479A 2006-05-09 2007-05-09 抗ウイルス性ピリミジンヌクレオシド誘導体 Expired - Fee Related JP5261374B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0609178.9A GB0609178D0 (en) 2006-05-09 2006-05-09 Novel compounds
GB0609178.9 2006-05-09
PCT/GB2007/001677 WO2007129083A1 (en) 2006-05-09 2007-05-09 Anti-viral pyrimidine nucleoside derivatives

Publications (3)

Publication Number Publication Date
JP2009536188A JP2009536188A (ja) 2009-10-08
JP2009536188A5 JP2009536188A5 (enExample) 2011-01-13
JP5261374B2 true JP5261374B2 (ja) 2013-08-14

Family

ID=36637171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009508479A Expired - Fee Related JP5261374B2 (ja) 2006-05-09 2007-05-09 抗ウイルス性ピリミジンヌクレオシド誘導体

Country Status (22)

Country Link
US (3) US8329664B2 (enExample)
EP (1) EP2016081B1 (enExample)
JP (1) JP5261374B2 (enExample)
KR (1) KR101447522B1 (enExample)
CN (1) CN101443332B (enExample)
AT (1) ATE506367T1 (enExample)
AU (1) AU2007246814B2 (enExample)
BR (1) BRPI0711354A2 (enExample)
CA (1) CA2656780C (enExample)
CY (1) CY1111711T1 (enExample)
DE (1) DE602007014030D1 (enExample)
DK (1) DK2016081T3 (enExample)
EA (1) EA015178B1 (enExample)
ES (1) ES2365057T3 (enExample)
GB (1) GB0609178D0 (enExample)
IL (1) IL194806A (enExample)
NZ (1) NZ573377A (enExample)
PL (1) PL2016081T3 (enExample)
PT (1) PT2016081E (enExample)
SI (1) SI2016081T1 (enExample)
TW (1) TWI385172B (enExample)
WO (1) WO2007129083A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009486D0 (en) * 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
GB2452556A (en) * 2007-09-07 2009-03-11 Univ Leuven Kath Nucleoside analogues esterified at 3 and/or 5 positions by neutral non-polar amino acid, or oligopeptide thereof, for combating Varicella Zoster virus
US9260469B2 (en) * 2010-10-09 2016-02-16 Contravir Pharmaceuticals, Inc. Method of preparation of antiviral compounds and useful intermediates thereof
CN105037468A (zh) * 2010-10-09 2015-11-11 英希比泰克斯公司 制备抗病毒组合物的方法及其中间体的应用
MD4110C1 (ro) * 2010-10-21 2011-12-31 Валериу РУДИК Preparat antiherpetiс
KR101875997B1 (ko) * 2015-05-04 2018-07-06 엔 앤드 엔 파마세우티칼스 인크. 엔-메탄노카르바티미딘을 이용한 대상포진의 치료방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62255499A (ja) 1986-04-28 1987-11-07 Teijin Ltd 螢光性ヌクレオシド又はヌクレオチド
EP0346108A3 (en) 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
YU43193A (sh) 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
GB9708611D0 (en) 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
GB9716231D0 (en) 1997-07-31 1997-10-08 Amersham Int Ltd Base analogues
MXPA02000763A (es) 1999-07-22 2002-08-12 Newbiotics Inc Activacion terapeutica catalizada por enzima.
MXPA02000761A (es) 1999-07-22 2002-08-12 Newbiotics Inc Agentes terapeuticos anti-infecciosos catalizados por enzima.
CN1391486A (zh) 1999-07-22 2003-01-15 新生物公司 治疗对治疗有抗性的肿瘤的方法
GB0009486D0 (en) * 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
GB0011203D0 (en) * 2000-05-09 2000-06-28 Univ Cardiff Chemical compounds
MY141594A (en) * 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CA2490191C (en) 2002-06-28 2010-08-03 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside prodrugs for treating flaviviridae infections
EP1745573A4 (en) * 2003-03-20 2010-05-26 Microbiol Quimica Farmaceutica PROCESS FOR PREPARING 2-DEOXY-BETA-L-NUCLEOSIDES
US20050137141A1 (en) 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
JP4856638B2 (ja) 2004-06-07 2012-01-18 アナディス・ファーマシューティカルズ・インコーポレイテッド ３−β−Ｄ−リボフラノシルチアゾロ［４，５−ｄ］ピリミジンヌクレオシドおよびその使用

Also Published As

Publication number Publication date
EA200870505A1 (ru) 2009-04-28
IL194806A (en) 2015-08-31
CA2656780A1 (en) 2007-11-15
US20150072948A1 (en) 2015-03-12
SI2016081T1 (sl) 2011-09-30
DK2016081T3 (da) 2011-06-20
JP2009536188A (ja) 2009-10-08
US8859512B2 (en) 2014-10-14
EA015178B1 (ru) 2011-06-30
US20130096079A1 (en) 2013-04-18
DE602007014030D1 (de) 2011-06-01
IL194806A0 (en) 2009-09-22
PT2016081E (pt) 2011-06-28
CN101443332B (zh) 2011-11-09
KR20090042204A (ko) 2009-04-29
BRPI0711354A2 (pt) 2011-09-27
EP2016081A1 (en) 2009-01-21
PL2016081T3 (pl) 2011-12-30
US8329664B2 (en) 2012-12-11
TW200813066A (en) 2008-03-16
US20100222295A1 (en) 2010-09-02
NZ573377A (en) 2011-03-31
AU2007246814B2 (en) 2012-07-19
CY1111711T1 (el) 2015-10-07
ATE506367T1 (de) 2011-05-15
WO2007129083A1 (en) 2007-11-15
CN101443332A (zh) 2009-05-27
GB0609178D0 (en) 2006-06-21
CA2656780C (en) 2015-04-28
US9427447B2 (en) 2016-08-30
EP2016081B1 (en) 2011-04-20
ES2365057T3 (es) 2011-09-21
AU2007246814A1 (en) 2007-11-15
TWI385172B (zh) 2013-02-11
KR101447522B1 (ko) 2014-10-06

Similar Documents

Publication Publication Date Title
JP4923216B2 (ja) 化合物
KR101612642B1 (ko) 테노포비어 알라펜아미드 헤미푸마레이트
JP5261374B2 (ja) 抗ウイルス性ピリミジンヌクレオシド誘導体
JP2002525374A (ja) 抗ウイルスプリン誘導体
IL228220A (en) Tricyclic inhibitors of the gyrase enzyme
WO2009005693A1 (en) Novel hiv reverse transcriptase inhibitors
ITMI951450A1 (it) Esteri acilici di amminoacidi achirali di gangiclovir e relativi derivati
EP1123935B1 (en) 3'-Fluorinated guanosine derivatives for the treatment or prophylaxis of HBV or retroviral infections
ES2357768T3 (es) Ácidos 2-(3-fenil-2-piperazinil-2,4-dihidroquinazolin-4-il)-acéticos como agentes antivirales, especialmente contra citomegalovirus.
WO2013063012A1 (en) Myxovirus therapeutics, compounds, and uses related thereto
JPWO2006082821A1 (ja) ヘルペスウイルスが関与する疾患の予防若しくは治療剤
US20170114087A1 (en) Method of preparation of antiviral compounds and useful intermediates thereof
US20250332276A1 (en) Inhibitors of Molluscum Contagiosum Infection and Methods Using the Same
US20070135436A1 (en) Chemical compounds
WO2025193760A1 (en) Quinazolinone compounds for treatment of hbv
CN119462821A (zh) 新型GalNAc的靶向递送片段及其制备和应用
KR100290533B1 (ko) 항바이러스 활성을 가지는 2-아미노퓨린
JPWO2001064693A1 (ja) ホスホナートヌクレオチド化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130426

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160502

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees